MC-Val-Cit-PAB-carfilzomib is a synthetic compound that belongs to the class of proteasome inhibitors, specifically designed for targeted cancer therapy. It is a conjugate of carfilzomib, a potent proteasome inhibitor used in the treatment of multiple myeloma, linked to a peptide-based moiety that enhances its selectivity and reduces systemic toxicity. The structure typically includes a valine-citrulline (Val-Cit) dipeptide, which is cleaved by specific enzymes in the tumor microenvironment, releasing the active drug. This mechanism allows for a more localized therapeutic effect, minimizing adverse effects on healthy tissues. The compound is characterized by its ability to induce apoptosis in cancer cells by disrupting protein homeostasis, leading to the accumulation of pro-apoptotic factors. Additionally, its pharmacokinetic properties are designed to optimize bioavailability and efficacy. Overall, MC-Val-Cit-PAB-carfilzomib represents a promising advancement in targeted cancer therapies, particularly for patients with relapsed or refractory multiple myeloma.

MC-Val-Cit-PAB-carfilzomib

2055896-83-6: MC-Val-Cit-PAB-carfilzomib is a synthetic compound that belongs to the class of proteasome inhibitors, specifically designed for targeted cancer therapy. It is a conjugate of carfilzomib, a potent proteasome inhibitor used in the treatment of multiple myeloma, linked to a peptide-based moiety that enhances its selectivity and reduces systemic toxicity. The structure typically includes a valine-citrulline (Val-Cit) dipeptide, which is cleaved by specific enzymes in the tumor microenvironment, releasing the active drug. This mechanism allows for a more localized therapeutic effect, minimizing adverse effects on healthy tissues. The compound is characterized by its ability to induce apoptosis in cancer cells by disrupting protein homeostasis, leading to the accumulation of pro-apoptotic factors. Additionally, its pharmacokinetic properties are designed to optimize bioavailability and efficacy. Overall, MC-Val-Cit-PAB-carfilzomib represents a promising advancement in targeted cancer therapies, particularly for patients with relapsed or refractory multiple myeloma.

4-((4S,7S,10S,13S)-10-Benzyl-7-isobutyl-15-methyl-13-((R)-2-methyloxirane-2-carbonyl)-2,5,8,11-tetraoxo-4-phenethyl-3,6,9,12-tetraazahexadecyl)-4-(4-((S)-2-((S)-2-(6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1

<p>MC-Val-Cit-PAB-carfilzomib: ADC drug-linker with carfilzomib for potent antitumor effect.</p>

CAS 2055896-83-6

MC-Val-Cit-PAB-carfilzomib

4-((4S,7S,10S,13S)-10-Benzyl-7-isobutyl-15-methyl-13-((R)-2-methyloxirane-2-carbonyl)-2,5,8,11-tetraoxo-4-phenethyl-3,6,9,12-tetraazahexadecyl)-4-(4-((S)-2-((S)-2-(6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1

Ref: 54-OR1070270

MC-Val-Cit-PAB-carfilzomib iodide

Ref: TM-T18320